scholarly journals Characteristic of infectious status in patients with acutely decompencated chronic heart failure and its impact on annual prognosis

Kardiologiia ◽  
2019 ◽  
Vol 59 (8S) ◽  
pp. 56-62
Author(s):  
V. A. Kostenko ◽  
M. Yu. Sitnikova ◽  
E. A. Skorodumova ◽  
E. G. Skorodumova ◽  
A. N. Fedorov ◽  
...  
Keyword(s):  
Heart Failure ◽  
Intestinal Bacteria ◽  
Mycoplasma Hominis ◽  
Chronic Obstructive ◽  
Infectious Agents ◽  
Gram Negative ◽  
Inflammatory Stress ◽  
Barr Virus ◽  
Epstein Barr ◽  
One Year

Aim. The assessment of infectious status in patients with acutely decompensated chronic heart faiure (ADCHF) without evident signs of acute inflammatory stress and its impact on the 1 year prognosis.Material and methods. Totally, 65 patients with ADCHF of ischemic origin investigated, age 67,3±2,3 y.o. All patients were taken markers of phagocytosis and inflammatory stress as well as antibodies to Streptococcus, Cytomegalovirus (CMV), Epstein-Barr virus (VEB), Candida albicans, Toxoplasma gondii, Aspergillus, Mycoplasma hominis and pneumonia and also level of lipopolysaccharids (LPS) of gram-negative bacteriae.Results. More often LPS of gram-negative bacteriae were revealed in patients with ADCHF and further in decreasing order – antibodies to CMV, VEB, Streptococcus, Candida, Aspergillus and LPS. All patients have been infected by at least 2 pathogens, more than 90 % of them had 3 ones or more. Mortality in first 12 months observation correlated with quantity of patient`s pathogenic patterns (r=0,52, p=0,004). Dependency of one-year mortality from degree of viral-bacterial mixt contamination was almost linear. CMV was a monopathogen with strongest correlation with mortality (r=0,39, p=0,001). In patients with more significant infection bigger rate of re-hospitalizations about new ADCHF correlated with number of pathogens was observed (r=0,61, p=0,001).Conclusion. Chronic latent infection with a significant number of pathogens is characteristic of patients with low-ejection ADCHF of ischemic genesis with a significant number of pathogens: more than 90 % of patients had three or more. The most common exogenous pathogens in the study sample of patients with chronic obstructive heart failure were CMV, EBV, and hemolytic streptococcus, of the potentially endogenous ones, gram-negative intestinal bacteria. The number of infectious agents in patients with chronic obstructive heart failure has a direct correlation with deaths and re-admission to hospital with total heart failure within 1 year after discharge from the hospital.

Infectious antibodies in systemic lupus erythematosus patients

Lupus ◽  
2009 ◽  
Vol 18 (13) ◽  
pp. 1129-1135 ◽  
Author(s):  
Y. Berkun ◽  
G. Zandman-Goddard ◽  
O. Barzilai ◽  
M. Boaz ◽  
Y. Sherer ◽  
...  
Keyword(s):  
Lupus Erythematosus ◽  
Epstein Barr Virus ◽  
Viral Capsid ◽  
Infectious Agents ◽  
Viral Capsid Antigen ◽  
Igg Antibodies ◽  
Systemic Lupus ◽  
Early Antigen ◽  
Barr Virus ◽  
Epstein Barr

Infections can act as environmental triggers that induce or promote systemic lupus erythematosus (SLE) in genetically predisposed individuals. New technologies, developed recently, enable simultaneous assessment of multiple antibodies. Antibodies to specific infectious agents may shed light into the mechanisms of induction of SLE. The aim of this study was to investigate the prevalence of seropositivity and the titers of antibodies to bacterial, viral, and parasitic agents in SLE patients compared with non-autoimmune controls. Sera from 260 individuals (120 SLE patients and 140 controls) were tested by the BioPlex 2200 Multiplexed Immunoassay method (BioRad) for the prevalence and titers of antibodies to eight infectious agents (Epstein—Barr virus: early antigen IgG, nuclear antigen IgG, viral capsid antigen IgG and IgM, heterophile IgM; cytomegalovirus IgG and IgM; Toxoplasma gondii IgG and IgM; rubella IgG and IgM; Treponema pallidum TPr15G, TPr17G, TPr47G; herpes simplex virus type 1 and 2 IgG; hepatitis C virus and hepatitis B core antibodies. Cytomegalovirus IgM and Epstein—Barr virus early antigen IgG (but not other Epstein—Barr virus antigens) were significantly more prevalent in SLE patients than in controls. Conversely, positive titers of hepatitis B core and rubella IgG antibodies were less prevalent in the SLE patients than in controls. Other differences in titer positivity prevalence were not detected between patients and controls. The titers of the cytomegalovirus IgM, Toxoplasma IgG, Epstein—Barr virus early antigen, and viral capsid antigen IgG antibodies were significantly higher in SLE compared with controls. Our data suggest the importance of previous exposure to infectious agents in the induction and the prevention of SLE. Lupus (2009) 18, 1129—1135.

Histopathologic, Immunohistochemical Features and Profile of Viral Antigens in Patients with Myocarditis

2015 ◽  
Vol 1085 ◽  
pp. 447-452 ◽  
Author(s):  
Yuliya Rogovskaya ◽  
Roman Botalov ◽  
Vyacheslav Ryabov
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Interstitial Fibrosis ◽  
Morphological Changes ◽  
Parvovirus B19 ◽  
Consensus Definition ◽  
Barr Virus ◽  
Epstein Barr ◽  
Group 2 ◽  
The Right

We studied medical records and endomyocardial biopsies of patients with morphological confirmed lymphocytic myocarditis. The patients were divided into two groups: 1 - patients with arrhythmias; group 2 - patients with predominance syndrome heart failure. Morphological verification of myocarditis was based on World Heart Federation Consensus definition of Inflammatory Cardiomyopathy, 1997. Immunohistological study was performed to identify antigens of cardiotrophic viruses. We revealed some features in topic and character of morphological changes in depending on clinical scenario of myocarditis. In patients with chronic heart failure due to myocarditis revealed a high incidence of expression of LMP-antigen Epstein-Barr virus, the lack of expression of adenovirus antigens. Arrhythmic presentation of myocarditis was characterized by a high frequency of expression of enteroviral VP-1 antigen and the type 1 antigen herpes virus. We were not detected expression of the VP-2 antigen parvovirus B19. As a result the most severe inflammatory changes and interstitial fibrosis of intraventricular septum, widespread damage of myocytes the severe myocardial remodeling was found in patients with presentation of myocarditis by chronic heart failure. Interstitial fibrosis of the outflow tracts of the right ventricle, the low activity of inflammation and mild fibrotic changes were feature of arrhythmic scenario of myocarditis.

scholarly journals The uninvited guests of our microbiome: Helicobacter pylori and Epstein-Barr virus and their role in gastric cancerogenesis

2021 ◽  
Vol 75 (1) ◽  
pp. 611-619
Author(s):  
Magdalena Dzikowiec ◽  
Dorota Pastuszak-Lewandoska
Keyword(s):  
Gastric Cancer ◽  
Epstein Barr Virus ◽  
Human Microbiome ◽  
Infectious Agents ◽  
Gastrointestinal Microbiome ◽  
Barr Virus ◽  
Epstein Barr ◽  
H Pylori ◽  
Development Of Gastric Cancer

Abstract It is well established that human body is an ecosystem for numerous microorganisms: bacteria, fungi, eukaryotic parasites, and viruses. They form a “microbiome” that under conditions of homeostasis remains in a friendly mutual relationship with the host. However, the composition and diversity of this microbe community is dynamic and can be changed under the influence of environmental factors, such as diet, antibiotic therapy, lifestyle, and the host’s genotype and immunity. The result of gut microbiome dysbiosis can lead even to cancer. The aim of this review is the description of the healthy gastrointestinal microbiome and the role of two infectious agents: Gram-negative bacteria Helicobacter pylori and Epstein-Barr virus in the development of gastric cancer in terms of gut dysbiosis. H. pylori is the most important pathogen of gastric microbiome with clear impact on its diversity. Coinfection with Epstein-Barr virus causes chronic gastritis, and the inflammatory process is significantly increased. The process of carcinogenesis begins with chronic inflammation that causes atrophic gastritis, intestinal metaplasia, dysplasia, and finally cancer. It has been proven that chronic inflammatory infection caused by infectious agents increases the risk of stomach cancer. Molecular methods that are progressively used to explore the human microbiome provide hope that this knowledge will be used for future diagnoses and therapy in the state of its dysbiosis and in cases of gastric cancer.

scholarly journals Epstein--Barr virus positive diffuse large B-cell lymphoma transformed into angioimmunoblastic T-cell lymphoma after treatment

2021 ◽  
Author(s):  
Chaoyu Wang ◽  
YI Gong ◽  
Xiping Liang ◽  
Rui Chen
Keyword(s):  
Epstein Barr Virus ◽  
Chemotherapy Regimen ◽  
Cell Lymphoma ◽  
Subsequent Development ◽  
B Cell Lymphoma ◽  
Poor Response ◽  
Barr Virus ◽  
Large B Cell Lymphoma ◽  
Epstein Barr ◽  
One Year

To date, there is no report on the subsequent development of AITL in patients with EBV-positive DLBCL. We performed a rare case of EBV-positive AITL developing one year after initial diagnosis of EBV-positive DLBCL. The patient showed poor response to the chemotherapy regimen, and poor surviva

scholarly journals The Role of Epstein-Barr Virus in Adults With Bronchiectasis: A Prospective Cohort Study

2020 ◽  
Vol 7 (8) ◽  
Author(s):  
Chun-Lan Chen ◽  
Yan Huang ◽  
Miguel Angel Martinez-Garcia ◽  
Jing-Jing Yuan ◽  
Hui-Min Li ◽  
...  
Keyword(s):  
Epstein Barr Virus ◽  
Quantitative Polymerase Chain Reaction ◽  
Induced Sputum ◽  
Chronic Obstructive ◽  
Healthy Controls ◽  
Viral Loads ◽  
Barr Virus ◽  
Opportunistic Bacteria ◽  
Ebv Dna ◽  
Epstein Barr

Abstract Background Epstein-Barr virus (EBV) is implicated in the progression of chronic obstructive pulmonary disease. We aimed to determine whether EBV correlates with bronchiectasis severity, exacerbations, and progression. Methods We collected induced sputum in healthy controls and spontaneous sputum at 3–6-month intervals and onset of exacerbations in bronchiectasis patients between March 2017 and October 2018. EBV DNA was detected with quantitative polymerase chain reaction. Results We collected 442 sputum samples from 108 bronchiectasis patients and 50 induced sputum samples from 50 healthy controls. When stable, bronchiectasis patients yielded higher detection rates of EBV DNA (48.1% vs 20.0%; P = .001), but not viral loads (mean log10 load, 4.45 vs 4.76; P = .266), compared with controls; 64.9% of patients yielded consistent detection status between 2 consecutive stable visits. Neither detection rate (40.8% vs 48.1%; P = .393) nor load (mean log10 load, 4.34 vs 4.45; P = .580) differed between the onset of exacerbations and stable visits, nor between exacerbations and convalescence. Neither detection status nor viral loads correlated with bronchiectasis severity. EBV loads correlated negatively with sputum interleukin-1β (P = .002), CXC motif chemokine-8 (P = .008), and tumor necrosis factor–α levels (P = .005). Patients initially detected with, or repeatedly detected with, EBV DNA had significantly faster lung function decline and shorter time to next exacerbations (both P < .05) than those without. Detection of EBV DNA was unrelated to influenza virus and opportunistic bacteria (all P > .05). The EBV strains detected in bronchiectasis patients were phylogenetically homologous. Conclusions Patients with detection of EBV DNA have a shorter time to bronchiectasis exacerbations. EBV may contribute to bronchiectasis progression.

Unexpected toxicity (UT) and opportunistic infections (OI) after rituximab-containing therapy for non-Hodgkin's lymphoma (NHL)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e19546-e19546
Author(s):  
M. Hentrich ◽  
A. Gerl ◽  
L. Lutz ◽  
M. Karthaus ◽  
X. Schiel
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Antimicrobial Therapy ◽  
Opportunistic Infections ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Lymphocytic Leukemia ◽  
Pneumocystis Jirovecii Pneumonia ◽  
Barr Virus ◽  
Epstein Barr

e19546 Background: Rituximab (R) is increasingly used for the treatment of B-NHL. Most adverse events are mild to moderate. In rare cases, however, R may be associated with severe UT and OI. Methods: The records of consecutive pts treated at 2 institutions from 01/06 to 12/08 with R-containing chemotherapy or R-maintenance therapy (R-M) for NHL were analyzed for severe UT and OI. UT was considered as related to R if it could not be explained otherwise. Results: 99 pts were included in the cohort study. Pts received a median of 6 cycles (range 1 - 18) of R. A total of 517 cycles of R were evaluable for OI or UT. 7 of 99 pts (7%) (2 females, 5 males) with a median age of 69.5 yrs (range 41–76) experienced UT (n=4) or OI (n=3). UT consisted of interstitial pneumonitis (IP) in 2 pts after 8 and 6 cycles of R-CHOP for diffuse large cell lymphoma (DLCL), a case of congestive heart failure (NYHA III°) after 6x R-CHOP + 2x R-M for follicular lymphoma (FL) and a case of grade 4 pancytopenia lasting for 22 days following 2x R-FC for chronic lymphocytic leukemia. IP completely resolved after initiation of prednisone (n=1) or under empiric antimicrobial therapy (n=1). Congestive heart failure improved under appropriate therapy and the pt received 2 more cycles of R-M. Pancytopenia slowly recovered under therapy with G-CSF, R was terminated. OI consisted of pneumocystis jirovecii pneumonia after 5x R-CHOP-14 for DLCL, Epstein-Barr-virus (EBV)-associated hepatitis after 5x R-CHOP-21 for relapsed FL and generalized herpes zoster following 6x R-bendamustine (RB) + 1x R-M for recurrent BALT-lymphoma. R was restarted in the latter 2 pts. Infections resolved under antimicrobial therapy. EBV-hepatitis improved spontaneously. Moreover, 2 pts were transferred to us for therapy of enterovirus-induced encephalitis after 6x R-CHOP-21 + 2x R-M for FL (n=1) and cerebral toxoplasmosis in a pt heavily pretreated with R-containing therapy for relapsed mantle cell lymphoma (n=1). Conclusions: Severe UT and OI are rare but potentially fatal complications. Awareness of UT/OI, rapid diagnostic proceedings and, whenever possible, initiation of therapy are essential. In selected cases reexposure of R may be feasible. No significant financial relationships to disclose.

SLAVE TORCH—infectious Agents for Hepatitis in Infants

PEDIATRICS ◽  
1982 ◽  
Vol 69 (1) ◽  
pp. 132-132
Author(s):  
Yehezkel Naveh
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Epstein Barr Virus ◽  
Infectious Agents ◽  
Varicella Zoster ◽  
Barr Virus ◽  
B Virus ◽  
Coxsackie B Virus ◽  
Epstein Barr ◽  
Coxsackie B

Despite the fact that there are more infectious agents causing the hepatitis syndrome in infants than are specified by the well-known term "TORCH," pediatricians are still satisfied with this term. We suggest using the more appropriate "SLAVE TORCH"1 which encompasses all the infectious agents implicated in this syndrome: S Syphilis; septicemia L Listeria A Australia Ag & Ab; adenovirus V Varicella zoster; vaccinia E Epstein-Barr virus (EBV) T Toxoplasma O Others like urinary tract infection R Rubella C Cytomegalovirus; Coxsackie B virus H Herpesvirus simplex

scholarly journals Imatinib for right heart failure in COPD

2018 ◽  
Vol 9 (1) ◽  
pp. 204589401881697 ◽  
Author(s):  
Philipp Douschan ◽  
Gabor Kovacs ◽  
Vasile Foris ◽  
Maria Kuehnelt-Leddihn ◽  
Horst Olschewski
Keyword(s):  
Heart Failure ◽  
Side Effects ◽  
Kinase Inhibitor ◽  
Right Heart Failure ◽  
Chronic Obstructive ◽  
Right Heart ◽  
Obstructive Pulmonary Disease ◽  
Increased Risk ◽  
Therapy Option ◽  
One Year

Severe pulmonary hypertension (PH) is rare in chronic obstructive pulmonary disease (COPD). Pulmonary arterial hypertension drugs are vasodilators and may cause severe side effects in these patients. Hence, they are not recommended except in right heart failure on an individual basis. Imatinib, a tyrosine-kinase-inhibitor, has no direct vasodilator effects but significantly improved hemodynamics and exercise capacity in PAH but its use was associated with an increased risk for subdural hematomas in anticoagulated patients. We report on a COPD patient with right heart failure who did not recover with a phosphodiesterase-5-inhibitor or a soluble-guanylate-cyclasestimulator alone but with imatinib as add-on therapy. After one year of treatment, pulmonary vascular resistance (10.8 WU to 2.9 WU), NT-proBNP (4144 pg/mL to 363 pg/mL), and symptoms (WHO FC IV to III, 6MWD bedridden to 303 m) improved without major side effects. Imatinib may be a therapy option in patients with severe PH due to lung disease and right heart failure where other drugs have failed.

Sign in / Sign up

Export Citation Format

Share Document